Author

B. E. Heaton

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 1 Assay:fluorescence / live-cell microscopy· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. T. Harding· 3 shared N. S. Heaton· 3 shared H. M. Froggatt· 2 shared R. R. Chaparian· 2 shared A. D. Davidson· 1 shared A. Karlsson· 1 shared A. Kerelsky· 1 shared A. P. Possemato· 1 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

A. T. Harding

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Influenza viral particles harboring the SARS-CoV-2 spike RBD as a combination respiratory disease vaccine

R. R. Chaparian, A. T. Harding, K. Riebe, A. Karlsson, G. D. Sempowski, N. S. Heaton, B. E. Heaton

This paper develops a combination vaccine using recombinant influenza A virus to deliver SARS-CoV-2 spike RBD, showing protection against both pathogens.

bioRxiv · Apr 30, 2021 · PreprintMicrobiology

The FDA-approved drug Alectinib compromises SARS-CoV-2 nucleocapsid phosphorylation and inhibits viral infection in vitro

T. M. Yaron, B. E. Heaton, T. M. Levy, J. L. Johnson, T. X. Jordan, B. M. Cohen, A. Kerelsky, T.-Y. Lin, K. M. Liberatore, D. K. Bulaon, E. R. Kastenhuber, M. N. Mercadante, K. Shobana-Ganesh, L. He, R. E. Schwartz, , M Kavanagh-Williamson

This study identifies Alectinib as an FDA-approved drug that inhibits SARS-CoV-2 nucleocapsid phosphorylation and viral replication in vitro by targeting host kinases.

bioRxiv · Aug 14, 2020 · PreprintMicrobiology

ETV7 limits antiviral gene expression and control of SARS-CoV-2 and influenza viruses

H. M. Froggatt, A. T. Harding, B. E. Heaton, N. S. Heaton

This study identifies ETV7 as a negative regulator of antiviral interferon-stimulated genes important for controlling influenza and SARS-CoV-2 infections.

bioRxiv · Jul 31, 2020 · PreprintMicrobiology

Development of a fluorescence based, high-throughput SARS-CoV-2 3CLpro reporter assay

H. M. Froggatt, B. E. Heaton, N. S. Heaton

This paper develops a fluorescence-based, high-throughput assay to screen for SARS-CoV-2 3CLpro inhibitors using a GFP-derived reporter that fluoresces after protease cleavage.

bioRxiv · Jun 24, 2020Microbiology